ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Impact of structured oral care strategies on oral mucositis in patients receiving 5-fluorouracil: a retrospective cohort study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOral mucositis (OM) is a frequent and debilitating complication of 5-fluorouracil (5-FU)-based chemotherapy, compromising patients' quality of life and treatment adherence. This study aimed to evaluate the impact of a structured oral care strategy (OCS), including photobiomodulation (PBM), on the severity, onset, and duration of OM in patients with solid tumors receiving 5-FU-based regimens.
methodsThis single-center study included 69 patients treated between 2020 and 2022 and was retrospectively registered (Ethics Committee approval No. 5.089.912/2021). All participants received standardized OCS before and during chemotherapy, consisting of dental examination, oral hygiene instructions, infection control measures, and PBM. PBM was delivered once daily during the first two days of each 5-FU chemotherapy cycle. Associations were analyzed using Chi-square tests and odds ratios.
resultsAll patients developed OM, predominantly grade 1 (40.6%) or grade 2 (52.2%), while only 7.2% experienced grade 3 lesions. Two PBM sessions were significantly associated with reduced onset, severity, and duration of OM, particularly among patients receiving FOLFIRINOX, for whom the risk of OM decreased 9.1-fold, and among neutropenic patients (p = 0.042). Conversely, the FOLFOX regimen was associated with earlier onset (p = 0.004) and greater severity (p = 0.026); however, two PBM sessions remained beneficial, reducing OM risk 1.35-fold.
conclusionStructured OCS incorporating PBM appears to be an effective, non-invasive approach to mitigate OM severity, onset, and duration in patients undergoing 5-FU-based chemotherapy. These findings support integrating dental care and PBM into routine oncology protocols. Prospective multicenter studies are warranted to validate and standardize this strategy.
Indexed as
Identifiers
41239052What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.